Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Bibliographic Details
Main Authors:	Francesca Palandri, Giuseppe Alberto Palumbo, Elena Maria Elli, Nicola Polverelli, Giulia Benevolo, Bruno Martino, Elisabetta Abruzzese, Mario Tiribelli, Alessia Tieghi, Roberto Latagliata, Francesco Cavazzini, Micaela Bergamaschi, Gianni Binotto, Monica Crugnola, Alessandro Isidori, Giovanni Caocci, Florian Heidel, Novella Pugliese, Costanza Bosi, Daniela Bartoletti, Giuseppe Auteri, Daniele Cattaneo, Luigi Scaffidi, Malgorzata Monica Trawinska, Rossella Stella, Fiorella Ciantia, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto Massimo Lemoli, Alessandra Iurlo, Nicola Vianelli, Michele Cavo, Massimo Breccia, Massimiliano Bonifacio
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-020-00392-1

Similar Items

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
by: Francesca Palandri, et al.
Published: (2023-08-01)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
by: Francesca Palandri, et al.
Published: (2023-05-01)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
by: Francesca Palandri, et al.
Published: (2023-07-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
by: F. Palandri, et al.
Published: (2022-06-01)

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia
by: Alessandro Costa, et al.
Published: (2024-01-01)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
by: Francesca Palandri, et al.
Published: (2012-06-01)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
by: Giuseppe Auteri, et al.
Published: (2021-06-01)

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis
by: Marco Romano, et al.
Published: (2017-10-01)

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia
by: matteo molica, et al.
Published: (2020-08-01)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
by: Giuseppe Auteri, et al.
Published: (2023-02-01)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
by: Francesca Palandri, et al.
Published: (2021-12-01)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
by: Roberto Latagliata, et al.
Published: (2016-09-01)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01)

IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY.
by: Giuseppe Auteri, et al.
Published: (2023-04-01)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
by: Massimo Breccia, et al.
Published: (2023-08-01)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
by: Massimo Breccia, et al.
Published: (2022-07-01)

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
by: Francesca Palandri, et al.
Published: (2021-09-01)

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
by: Martina Barone, et al.
Published: (2021-10-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
by: Martina Barone, et al.
Published: (2020-01-01)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
by: Matteo Dragani, et al.
Published: (2020-11-01)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
by: Simona Soverini, et al.
Published: (2019-12-01)

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
by: Monica Barone, et al.
Published: (2021-11-01)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
by: Massimo Breccia, et al.
Published: (2021-03-01)

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached
by: Massimo Breccia
Published: (2020-02-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib
by: Massimo Breccia
Published: (2015-10-01)

Nilotinib: selective inhibitor as second-line therapy
by: Massimo Breccia
Published: (2015-10-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Massimo Breccia, et al.
Published: (2011-05-01)

AIDS, conflict and the media in Africa: risks in reporting bad data badly
by: Spiegel Paul, et al.
Published: (2005-12-01)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
by: Maria Cristina Puzzolo, et al.
Published: (2022-09-01)

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
by: Monica Bocchia, et al.
Published: (2018-05-01)

NEW STRATEGIES FOR STEM CELL MOBILIZATION
by: Roberto Lemoli
Published: (2012-01-01)

Il linguaggio scolastico ticinese: alcune osservazioni e peculiarità
by: Roberto Crugnola
Published: (2008-11-01)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
by: Mohammad Houshmand, et al.
Published: (2022-06-01)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
by: Lucia Catani, et al.
Published: (2021-09-01)

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
by: Michele Malagola, et al.
Published: (2021-03-01)

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia
by: Sara Galimberti, et al.
Published: (2024-03-01)

The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
by: Massimiliano Bonifacio, et al.
Published: (2021-09-01)